Healthcare >> CEO Interviews >> September 14, 2001
DAN W. DENNEY, JR., founded Genitope Corporation in August 1996, and
currently serves as Chief Executive Officer. Since inventing Genitope's
patented High Throughput Gene Expression Technology (Hi-GET_), Dr.
Denney has successfully directed the mass production of patient-specific
idiotype vaccines, often thought of as 'cancer vaccines,' for B-cell
lymphoma. The idiotype vaccine includes a custom-made protein derived
from each patient's tumor cells and is currently being studied in a
Phase III clinical trial for its potential efficacy in delaying the
growth and spread of these tumors. Dr. Denney graduated with a BA degree
from Vanderbilt University. He worked for the Sloan-Kettering Cancer
Institute and Cetus Corporation before attending Stanford University
School of Medicine where he received his PhD in Microbiology and
Immunology, in the lab of Dr. Irving Weissman. He did his postdoctoral
research in the laboratory of Dr. Harden McConnell in the Chemistry
Department at Stanford University, where he was a Merck Fellow. Dr.
Denney then served as a Visiting Scholar at the University of Alberta in
Canada prior to founding Genitope. Profile
then an overview or picture of Genitope as it is now?
Dr. Denney: The company was founded five years ago to commercialize
